Physician profile
Mark Allen Grabarczyk
NPI 1134168941
$8,646.30
in general payments reported to CMS, 2019-2025
37 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $786 · 2021: $1,178 · 2022: $2,392 · 2023: $586 · 2024: $978 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,420.06 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $1,237.12 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Abiomed | $885.51 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $662.41 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $542.10 | 2019-2025 | Watchman Flx, Wolverine Coronary Cutting Balloon, Avvigo Guidance System |
| Atricure, INC. | $495.79 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System, Synergy Ablation System |
| Amgen INC. | $433.75 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $343.03 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $288.68 | 2019-2023 | Farxiga |
| Medtronic Vascular, INC. | $247.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $242.45 | 2019-2023 | |
| Cardiovascular Systems INC. | $188.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $162.05 | 2021-2023 | Verquvo |
| Teleflex LLC | $155.20 | 2021-2025 | Trapliner |
| Pfizer INC. | $151.52 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $135.24 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $122.44 | 2019 | |
| Abbott Laboratories | $119.33 | 2019-2025 | Diamondback Coronary, Xience Skypoint |
| Cvrx, INC. | $96.34 | 2023-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.79 | 2019-2023 | Jardiance |
| Philips North America LLC | $81.86 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Bq9) Coronary Ivus |
| E.R. Squibb & Sons, L.L.C. | $80.64 | 2019-2023 | Camzyos, Eliquis |
| Gilead Sciences, INC. | $65.18 | 2019 | |
| Surmodics, INC. | $48.84 | 2022-2023 | Pounce Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| Penumbra, INC. | $48.20 | 2019 | |
| Novo Nordisk INC | $46.74 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $33.70 | 2024 | Arcalyst |
| Terumo Medical Corporation | $31.43 | 2022-2025 | Glidewire |
| Kiniksa Pharmaceuticals, LTD. | $29.99 | 2022 | |
| Acist Medical Systems, INC. | $27.02 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $24.72 | 2019 | |
| Livanova USA, INC. | $22.99 | 2021 | |
| Angiodynamics, INC. | $19.55 | 2022 | |
| Cmp Pharma, INC. | $19.42 | 2022 | |
| Amarin Pharma, INC. | $15.99 | 2023 | |
| Irhythm Technologies, INC. | $14.43 | 2024 | Zio Xt Patch, Zio Monitor |
| Bard Peripheral Vascular, INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Grabarczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.